C. Kent Osborne, MD

COMMENTING ON the ACCRU study SC-1603, press conference moderator C. Kent Osborne, MD, Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston and Co-Director of the San Antonio Breast Cancer Symposium, said: “In patients who have breast cancer, I usually start treating hot flashes with venlafaxine, but I might start with oxybutynin now.”

“It is important to select the right patient for the best drug. If a patient has a depressive component, it could be due to sleeplessness from hot flashes or the cancer itself; in that case, I would use venlafaxine,” shared Dr. Osborne. ■

DISCLOSURE: Dr. Osborne has stock and other ownership interests in GeneTex; is a consultant/advisor for AstraZeneca, Genentech/Roche, Ventana Medical Systems; has patents, royalties, or other intellectual property associated with the book Diseases of the Breast; has given expert testimony for AstraZeneca; and has received reimbursement for travel, accommodations, or expenses from Ventana Medical Systems.